{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T09:07:00Z","timestamp":1768640820068,"version":"3.49.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The effectiveness of a 3<jats:sup>rd<\/jats:sup>dose of SARS-CoV-2 vaccines waned quickly in the Omicron-predominant period. In response to fast-waning immunity and the threat of Omicron variant of concern (VOC) to healthcare workers (HCWs), we conduct a non-randomized trial (ChiCTR2200055564) in which 38 HCWs volunteer to receive a homologous booster of inactivated vaccines (BBIBP-CorV) 6 months after the 3<jats:sup>rd<\/jats:sup>dose. The primary and secondary outcomes are neutralizing antibodies (NAbs) and the receptor-binding domain (RBD)-directed antibodies, respectively. The 4<jats:sup>th<\/jats:sup>dose recalls waned immunity while having distinct effects on humoral responses to different antigens. The peak antibody response to the RBD induced by the 4<jats:sup>th<\/jats:sup>dose is inferior to that after the 3<jats:sup>rd<\/jats:sup>dose, whereas responses to the N-terminal domain (NTD) of spike protein are further strengthened significantly. Accordingly, the 4<jats:sup>th<\/jats:sup>dose further elevates the peak level of NAbs against ancestral SARS-CoV-2 and Omicron BA.2, but not BA.1 which has more NTD mutations. No severe adverse events related to vaccination are recorded during the trial. Here, we show that redistribution of immune focus after repeated vaccinations may modulate cross-protective immune responses against different VOCs.<\/jats:p>","DOI":"10.1038\/s41467-022-34633-7","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T19:03:34Z","timestamp":1668193414000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["A fourth dose of the inactivated SARS-CoV-2 vaccine redistributes humoral immunity to the N-terminal domain"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8631-3264","authenticated-orcid":false,"given":"Ji","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caiguangxi","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yihao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liubing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhangping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liru","family":"Shang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruohui","family":"Mo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9692-3026","authenticated-orcid":false,"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7399-2579","authenticated-orcid":false,"given":"Sui","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4188-336X","authenticated-orcid":false,"given":"Haipeng","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,11]]},"reference":[{"key":"34633_CR1","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1056\/NEJMoa2114583","volume":"385","author":"EG Levin","year":"2021","unstructured":"Levin, E. G. et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N. Engl. J. Med. 385, e84 (2021).","journal-title":"N. Engl. J. Med."},{"key":"34633_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41421-022-00373-7","volume":"8","author":"Y Liu","year":"2022","unstructured":"Liu, Y. et al. Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine. Cell Discov. 8, 10 (2022).","journal-title":"Cell Discov."},{"key":"34633_CR3","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","volume":"579","author":"F Wu","year":"2020","unstructured":"Wu, F. et al. A new coronavirus associated with human respiratory disease in China. Nature 579, 265\u2013269 (2020).","journal-title":"Nature"},{"key":"34633_CR4","doi-asserted-by":"crossref","unstructured":"Cao, Y. et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 602, 657\u2013663 (2021).","DOI":"10.1038\/s41586-021-04385-3"},{"key":"34633_CR5","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMc2113468","volume":"385","author":"AR Falsey","year":"2021","unstructured":"Falsey, A. R. et al. SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3. N. Engl. J. Med. 385, 1627\u20131629 (2021).","journal-title":"N. Engl. J. Med."},{"key":"34633_CR6","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S0140-6736(22)00090-3","volume":"399","author":"C Kuhlmann","year":"2022","unstructured":"Kuhlmann, C. et al. Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose. Lancet 399, 625\u2013626 (2022).","journal-title":"Lancet"},{"key":"34633_CR7","doi-asserted-by":"publisher","first-page":"111009","DOI":"10.1016\/j.celrep.2022.111009","volume":"39","author":"V Stalls","year":"2022","unstructured":"Stalls, V. et al. Cryo-EM structures of SARS-CoV-2 Omicron BA.2 spike. Cell Rep. 39, 111009 (2022).","journal-title":"Cell Rep."},{"key":"34633_CR8","unstructured":"Agency, U.H.S. SARS-CoV-2 Variants of Concern and Variants under Investigation in England, Technical briefing 40 (2022)."},{"key":"34633_CR9","doi-asserted-by":"publisher","unstructured":"Khan, K. et al. Omicron sub-lineages BA.4\/BA.5 escape BA.1 infection elicited neutralizing immunity. medRxiv https:\/\/doi.org\/10.1101\/2022.04.29.22274477 (2022).","DOI":"10.1101\/2022.04.29.22274477"},{"key":"34633_CR10","unstructured":"Fireman, J.M.F.S.R.B.E.D.P.K.M.M.B.D.B. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19\u2014Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance\u2014VISION Network, 10 States, August 2021\u2013January 2022. Morbidity and Mortality Weekly Report 71 (2022)."},{"key":"34633_CR11","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1126\/science.abn7591","volume":"375","author":"A Muik","year":"2022","unstructured":"Muik, A. et al. Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera. Science 375, 678\u2013680 (2022).","journal-title":"Science"},{"key":"34633_CR12","doi-asserted-by":"crossref","unstructured":"Keeton, R. et al. T cell responses to SARS-CoV-2 spike cross-recognize Omicron. Nature 604, E25 (2022).","DOI":"10.1038\/s41586-022-04708-y"},{"key":"34633_CR13","doi-asserted-by":"crossref","unstructured":"Bar-On, Y.M. et al. Protection by 4th dose of BNT162b2 against Omicron in Israel. N. Engl. J. Med. 386, 1712\u20131720 (2022).","DOI":"10.1056\/NEJMoa2201570"},{"key":"34633_CR14","doi-asserted-by":"publisher","unstructured":"Regev-Yochay, G. et al. 4th Dose COVID mRNA Vaccines\u2019 Immunogenicity & Efficacy Against Omicron VOC. MedRxiv https:\/\/doi.org\/10.1101\/2022.02.15.22270948 (2022).","DOI":"10.1101\/2022.02.15.22270948"},{"key":"34633_CR15","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1038\/s41422-021-00541-6","volume":"31","author":"H Zhang","year":"2021","unstructured":"Zhang, H. et al. Time of day influences immune response to an inactivated vaccine against SARS-CoV-2. Cell Res. 31, 1215\u20131217 (2021).","journal-title":"Cell Res."},{"key":"34633_CR16","doi-asserted-by":"publisher","first-page":"4969","DOI":"10.1016\/j.cell.2021.07.025","volume":"184","author":"P Tong","year":"2021","unstructured":"Tong, P. et al. Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike. Cell 184, 4969\u20134980.e4915 (2021).","journal-title":"Cell"},{"key":"34633_CR17","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.immuni.2021.05.001","volume":"54","author":"HL Dugan","year":"2021","unstructured":"Dugan, H. L. et al. Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets. Immunity 54, 1290\u20131303.e1297 (2021).","journal-title":"Immunity"},{"key":"34633_CR18","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1016\/j.chom.2021.10.003","volume":"29","author":"R Keeton","year":"2021","unstructured":"Keeton, R. et al. Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner. Cell Host Microbe 29, 1611\u20131619.e1615 (2021).","journal-title":"Cell Host Microbe"},{"key":"34633_CR19","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/S1473-3099(21)00420-5","volume":"21","author":"M Tenbusch","year":"2021","unstructured":"Tenbusch, M. et al. Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2. Lancet Infect. Dis. 21, 1212\u20131213 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"34633_CR20","doi-asserted-by":"crossref","unstructured":"Gabriele Cerutti, Y.G. et al. Cryo-EM structure of the SARS-CoV-2 omicron spike. Cell Rep. 38, 110428 (2022).","DOI":"10.1016\/j.celrep.2022.110428"},{"key":"34633_CR21","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1056\/NEJMc2201849","volume":"386","author":"J Yu","year":"2022","unstructured":"Yu, J. et al. Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants. N. Engl. J. Med. 386, 1579\u20131580 (2022).","journal-title":"N. Engl. J. Med."},{"key":"34633_CR22","doi-asserted-by":"crossref","unstructured":"Wang, K. et al. Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants. Nature 603, 919\u2013925 (2022).","DOI":"10.1038\/s41586-022-04466-x"},{"key":"34633_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11296-5","volume":"10","author":"S Khurana","year":"2019","unstructured":"Khurana, S. et al. Repeat vaccination reduces antibody affinity maturation across different influenza vaccine platforms in humans. Nat. Commun. 10, 3338 (2019).","journal-title":"Nat. Commun."},{"key":"34633_CR24","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3389\/fimmu.2017.00238","volume":"8","author":"JJ Bergstrom","year":"2017","unstructured":"Bergstrom, J. J., Xu, H. & Heyman, B. Epitope-specific suppression of igg responses by passively administered specific IgG: evidence of epitope masking. Front. Immunol. 8, 238 (2017).","journal-title":"Front. Immunol."},{"key":"34633_CR25","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1097\/COH.0000000000000092","volume":"9","author":"S Moir","year":"2014","unstructured":"Moir, S. & Fauci, A. S. B-cell exhaustion in HIV infection: the role of immune activation. Curr. Opin. HIV AIDS 9, 472\u2013477 (2014).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"34633_CR26","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.cell.2021.12.033","volume":"185","author":"WF Garcia-Beltran","year":"2022","unstructured":"Garcia-Beltran, W. F. et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell 185, 457\u2013466.e454 (2022).","journal-title":"Cell"},{"key":"34633_CR27","doi-asserted-by":"publisher","unstructured":"Wang, Z. et al. Conserved neutralizing epitopes on the N-terminal domain of variant SARS-CoV-2 spike proteins. bioRxiv https:\/\/doi.org\/10.1101\/2022.02.01.478695 (2022).","DOI":"10.1101\/2022.02.01.478695"},{"key":"34633_CR28","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/s41590-020-0782-6","volume":"21","author":"Y Peng","year":"2020","unstructured":"Peng, Y. et al. Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat. Immunol. 21, 1336\u20131345 (2020).","journal-title":"Nat. Immunol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-34633-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-34633-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-34633-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T21:47:06Z","timestamp":1678571226000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-34633-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,11]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["34633"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-34633-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,11]]},"assertion":[{"value":"15 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6866"}}